226 related articles for article (PubMed ID: 31934875)
1. An Ototoxicity Grading System Within a Mobile App (OtoCalc) for a Resource-Limited Setting to Guide Grading and Management of Drug-Induced Hearing Loss in Patients With Drug-Resistant Tuberculosis: Prospective, Cross-Sectional Case Series.
Hollander C; Joubert K; Schellack N
JMIR Mhealth Uhealth; 2020 Jan; 8(1):e14036. PubMed ID: 31934875
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
[TBL] [Abstract][Full Text] [Related]
3. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Clin Infect Dis; 2020 Feb; 70(5):917-924. PubMed ID: 30963176
[TBL] [Abstract][Full Text] [Related]
4. Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Int J Tuberc Lung Dis; 2020 Jan; 24(1):65-72. PubMed ID: 32005308
[No Abstract] [Full Text] [Related]
5. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
[TBL] [Abstract][Full Text] [Related]
6. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
[TBL] [Abstract][Full Text] [Related]
7. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
Ramma L; Nhokwara PT; Rogers C
S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
[TBL] [Abstract][Full Text] [Related]
8. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
[TBL] [Abstract][Full Text] [Related]
9. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients.
Harris T; Bardien S; Schaaf HS; Petersen L; De Jong G; Fagan JJ
S Afr Med J; 2012 May; 102(6 Pt 2):363-6. PubMed ID: 22668907
[TBL] [Abstract][Full Text] [Related]
10. A longitudinal community-based ototoxicity monitoring programme and treatment effects for drug-resistant tuberculosis treatment, Western Cape.
Stevenson LJ; Biagio-de Jager L; Graham MA; Swanepoel W
S Afr J Commun Disord; 2022 Mar; 69(1):e1-e13. PubMed ID: 35384675
[TBL] [Abstract][Full Text] [Related]
11. An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal.
Appana D; Joseph L; Paken J
S Afr J Commun Disord; 2016 Nov; 63(1):e1-e12. PubMed ID: 28155306
[TBL] [Abstract][Full Text] [Related]
12. What Are the Current Audiological Practices for Ototoxicity Assessment and Management in the South African Healthcare Context?
Khoza-Shangase K; Masondo N
Int J Environ Res Public Health; 2020 Apr; 17(7):. PubMed ID: 32290287
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.
Ghafari N; Court R; Chirehwa MT; Wiesner L; Petersen L; Maartens G; Gumbo T; McIlleron H; Ramma L
Int J Audiol; 2020 Mar; 59(3):219-223. PubMed ID: 31739701
[No Abstract] [Full Text] [Related]
14. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.
Hong H; Budhathoki C; Farley JE
Int J Tuberc Lung Dis; 2018 Jun; 22(6):667-674. PubMed ID: 29862952
[TBL] [Abstract][Full Text] [Related]
15. OTOTOXICITY OF ANTIMYCOBACTERIAL THERAPY: MANIFESTATIONS, MECHANISMS OF MANAGEMENT AND CONTROL.
Makoyda I; Ostrovskyy М; Shevchuk-Budz U; Molodovets О; Zuban A
Wiad Lek; 2023; 76(12):2587-2592. PubMed ID: 38290021
[TBL] [Abstract][Full Text] [Related]
16. Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglycosides.
Human H; Hagen CM; de Jong G; Harris T; Lombard D; Christiansen M; Bardien S
Biochem Biophys Res Commun; 2010 Mar; 393(4):751-6. PubMed ID: 20171168
[TBL] [Abstract][Full Text] [Related]
17. Hearing loss in children treated for multidrug-resistant tuberculosis.
Seddon JA; Thee S; Jacobs K; Ebrahim A; Hesseling AC; Schaaf HS
J Infect; 2013 Apr; 66(4):320-9. PubMed ID: 22960077
[TBL] [Abstract][Full Text] [Related]
18. Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin.
Khoza-Shangase K; Prodromos M
S Afr J Commun Disord; 2021 Jan; 68(1):e1-e8. PubMed ID: 33567829
[TBL] [Abstract][Full Text] [Related]
19. Audiological monitoring of patients undergoing multidrug resistant tuberculosis treatment at Jigme Dorji Wangchuk National Referral Hospital and Gidakom Hospital, Bhutan.
Wangchuk P; Ram Adhikari T; Nima G; Dendup P
J Clin Tuberc Other Mycobact Dis; 2021 May; 23():100229. PubMed ID: 33898763
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials, ototoxicity grading scales and the audiologist's role in therapeutic decision making.
King KA; Brewer CC
Int J Audiol; 2018 Sep; 57(sup4):S89-S98. PubMed ID: 29276851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
